Compare UiPath Inc (PATH) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? UiPath Inc trades at $13.26 (market cap $6.81B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 8.5× UiPath Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| PATH | TAK | |
|---|---|---|
Market Cap | $6.81B | $58.16B |
Volume | 22,766,109 | 2,467,530 |
Sector | Technology | Health |
52-Week High | $19.29 | $19.05 |
52-Week Low | $9.38 | $13.23 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $5.61B | $86.04B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.25, up 1.15% with mixed technical signals showing bearish momentum but neutral oscillators. The company demonstrates improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though the stock faces near-term headwinds from valuation concerns and competitive pressures.
PATH presents a turnaround story with strong revenue growth and path to profitability, but faces execution risks amid competitive automation landscape. The consensus price target of $15.13 suggests 14% upside potential, though technical weakness and mixed analyst sentiment warrant caution. Key catalysts include AI platform adoption and enterprise expansion, while risks involve growth sustainability and margin pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
